Grifols S.A
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more
Grifols S.A (GIFLF) - Net Assets
Latest net assets as of June 2025: $7.60 Billion USD
Based on the latest financial reports, Grifols S.A (GIFLF) has net assets worth $7.60 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($19.77 Billion) and total liabilities ($12.17 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.60 Billion |
| % of Total Assets | 38.44% |
| Annual Growth Rate | 30.35% |
| 5-Year Change | 28.08% |
| 10-Year Change | 160.71% |
| Growth Volatility | 123.39 |
Grifols S.A - Net Assets Trend (2005–2024)
This chart illustrates how Grifols S.A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Grifols S.A (2005–2024)
The table below shows the annual net assets of Grifols S.A from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $8.61 Billion | +7.96% |
| 2023-12-31 | $7.97 Billion | -5.74% |
| 2022-12-31 | $8.46 Billion | +3.81% |
| 2021-12-31 | $8.15 Billion | +21.23% |
| 2020-12-31 | $6.72 Billion | -1.84% |
| 2019-12-31 | $6.85 Billion | +45.76% |
| 2018-12-31 | $4.70 Billion | +29.24% |
| 2017-12-31 | $3.63 Billion | -2.52% |
| 2016-12-31 | $3.73 Billion | +12.92% |
| 2015-12-31 | $3.30 Billion | +23.98% |
| 2014-12-31 | $2.66 Billion | +26.37% |
| 2013-12-31 | $2.11 Billion | +12.04% |
| 2012-12-31 | $1.88 Billion | +12.96% |
| 2011-12-31 | $1.66 Billion | +135.37% |
| 2010-12-31 | $707.39 Million | +22.27% |
| 2009-12-31 | $578.53 Million | +20.21% |
| 2008-12-31 | $481.28 Million | +25.28% |
| 2007-12-31 | $384.17 Million | +4.29% |
| 2006-12-31 | $368.35 Million | +558.39% |
| 2005-12-31 | $55.95 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Grifols S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 514.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $156.92 Million | 2.67% |
| Common Stock | $119.60 Million | 2.03% |
| Other Comprehensive Income | $4.83 Billion | 82.11% |
| Other Components | $776.28 Million | 13.19% |
| Total Equity | $5.88 Billion | 100.00% |
Grifols S.A Competitors by Market Cap
The table below lists competitors of Grifols S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
International Games System Co Ltd
TWO:3293
|
$5.35 Billion |
|
Grupo Aeroportuario del Centro Norte SAB de CV
NASDAQ:OMAB
|
$5.35 Billion |
|
Balchem Corporation
NASDAQ:BCPC
|
$5.36 Billion |
|
Pidilite Industries Limited
NSE:PIDILITIND
|
$5.36 Billion |
|
United Bankshares Inc
NASDAQ:UBSI
|
$5.35 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
$5.34 Billion |
|
DaVita HealthCare Partners Inc
NYSE:DVA
|
$5.34 Billion |
|
Lithia Motors Inc
NYSE:LAD
|
$5.34 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Grifols S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,827,166,000 to 5,883,727,000, a change of 56,561,000 (1.0%).
- Net income of 156,920,000 contributed positively to equity growth.
- Dividend payments of 962,000 reduced retained earnings.
- Other comprehensive income increased equity by 382,449,000.
- Other factors decreased equity by 481,846,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $156.92 Million | +2.67% |
| Dividends Paid | $962.00K | -0.02% |
| Other Comprehensive Income | $382.45 Million | +6.5% |
| Other Changes | $-481.85 Million | -8.19% |
| Total Change | $- | 0.97% |
Book Value vs Market Value Analysis
This analysis compares Grifols S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.15x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 71.91x to 1.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $0.13 | $9.53 | x |
| 2006-12-31 | $0.86 | $9.53 | x |
| 2007-12-31 | $0.78 | $9.53 | x |
| 2008-12-31 | $0.99 | $9.53 | x |
| 2009-12-31 | $1.17 | $9.53 | x |
| 2010-12-31 | $2.68 | $9.53 | x |
| 2011-12-31 | $5.40 | $9.53 | x |
| 2012-12-31 | $2.74 | $9.53 | x |
| 2013-12-31 | $3.09 | $9.53 | x |
| 2014-12-31 | $3.88 | $9.53 | x |
| 2015-12-31 | $4.82 | $9.53 | x |
| 2016-12-31 | $5.45 | $9.53 | x |
| 2017-12-31 | $5.30 | $9.53 | x |
| 2018-12-31 | $6.17 | $9.53 | x |
| 2019-12-31 | $7.04 | $9.53 | x |
| 2020-12-31 | $7.46 | $9.53 | x |
| 2021-12-31 | $8.98 | $9.53 | x |
| 2022-12-31 | $9.04 | $9.53 | x |
| 2023-12-31 | $8.57 | $9.53 | x |
| 2024-12-31 | $8.27 | $9.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Grifols S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.67%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.18%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 3.64x
- Recent ROE (2.67%) is below the historical average (14.92%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 45.78% | 4.87% | 0.64x | 14.72x | $19.97 Million |
| 2006 | 12.34% | 7.00% | 0.71x | 2.48x | $8.60 Million |
| 2007 | 22.91% | 12.48% | 0.75x | 2.45x | $49.46 Million |
| 2008 | 25.36% | 14.95% | 0.69x | 2.46x | $73.73 Million |
| 2009 | 26.13% | 16.20% | 0.55x | 2.93x | $91.33 Million |
| 2010 | 16.67% | 11.66% | 0.52x | 2.73x | $46.21 Million |
| 2011 | 3.03% | 2.80% | 0.31x | 3.49x | $-115.94 Million |
| 2012 | 13.68% | 9.79% | 0.47x | 3.00x | $69.01 Million |
| 2013 | 16.44% | 12.60% | 0.47x | 2.78x | $135.42 Million |
| 2014 | 17.69% | 14.01% | 0.40x | 3.18x | $204.44 Million |
| 2015 | 16.14% | 13.52% | 0.41x | 2.91x | $202.52 Million |
| 2016 | 14.66% | 13.47% | 0.40x | 2.72x | $173.31 Million |
| 2017 | 18.26% | 15.35% | 0.40x | 3.01x | $299.79 Million |
| 2018 | 14.12% | 13.30% | 0.36x | 2.95x | $174.09 Million |
| 2019 | 12.96% | 12.26% | 0.33x | 3.22x | $142.93 Million |
| 2020 | 12.11% | 11.58% | 0.35x | 2.99x | $107.71 Million |
| 2021 | 3.10% | 3.83% | 0.26x | 3.15x | $-420.94 Million |
| 2022 | 3.40% | 3.43% | 0.28x | 3.51x | $-404.71 Million |
| 2023 | 1.02% | 0.90% | 0.31x | 3.68x | $-523.40 Million |
| 2024 | 2.67% | 2.18% | 0.34x | 3.64x | $-431.45 Million |
Industry Comparison
This section compares Grifols S.A's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $308,328,125,500
- Average return on equity (ROE) among peers: 18.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Grifols S.A (GIFLF) | $7.60 Billion | 45.78% | 1.60x | $5.35 Billion |
| AbbVie Inc (ABBV) | $13.10 Billion | 35.24% | 10.50x | $390.88 Billion |
| Astellas Pharma Inc (ALPMF) | $1.06 Trillion | 7.80% | 0.36x | $16.93 Billion |
| Amgen Inc (AMGN) | $20.39 Billion | 20.58% | 0.79x | $196.91 Billion |
| Amarin Corporation PLC (AMRN) | $28.90 Million | 14.19% | 0.23x | $303.32 Million |
| AstraZeneca PLC (AZN) | $48.72 Billion | 21.05% | 1.34x | $296.35 Billion |
| Bayer AG (BAYZF) | $31.90 Billion | 14.21% | 1.58x | $21.61 Billion |
| Biogen Inc (BIIB) | $325.20 Million | 9.96% | 0.10x | $26.81 Billion |
| Bristol-Myers Squibb Company (BMY) | $5.08 Billion | 14.69% | 0.67x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $1.90 Trillion | 20.37% | 0.16x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $220.16 Million | 31.22% | 0.10x | $529.97 Million |